ADXN Addex Therapeutics Ltd - American Depositary Shares
ADXN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ADXN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
ADXN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 0 0.0%
- Buy 0 0.0%
- Hold 2 22.2%
- Sell 5 55.6%
- Strong Sell 2 22.2%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2024 | $-1.23 | — | — |
| Dec. 31, 2022 | $-0.23 | — | — |
| June 30, 2013 | $-1.61 | $-0.64 | -0.97% |
| Dec. 31, 2012 | $-1.55 | $-1.61 | 0.06% |
| June 30, 2012 | $-1.55 | $-1.61 | 0.06% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ADXN | — | — | — | — | — | — |
| OCS | — | — | — | — | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 2 filers · $274 total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 1 (+1 vs prior Q) | 3 (+2 vs prior Q) | 0 (-1 vs prior Q) | 0 (0 vs prior Q) | -407 |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| UBS Group AG | $268 | 47 | 97.81% | Shares |
| SBI Securities Co., Ltd. | $6 | 1 | 2.19% | Shares |
Activists & 5%+ owners 11 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Timothy Mark Dyer | June 23, 2025 | 12.94% | Amendment | — | SEC |
| Aug. 14, 2024 | — | Initial filing | — | SEC | |
| Growth Equity Opportunities Fund IV, LLC, New Enterprise Associates 15, L.P., NEA Partners 15, L.P., NEA 15 GP, LLC, Forest Baskett, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Scott D. Sandell ×7 filings | Aug. 5, 2024 | — | Initial filing | — | SEC |
| Undisclosed reporting person | Nov. 29, 2023 | — | Initial filing | — | SEC |
| Undisclosed reporting person | April 5, 2023 | — | Initial filing | — | SEC |
| Undisclosed reporting person | March 31, 2023 | — | Initial filing | — | SEC |
| Undisclosed reporting person | Nov. 23, 2022 | — | Initial filing | — | SEC |
| Undisclosed reporting person | Nov. 9, 2022 | — | Initial filing | — | SEC |
| Undisclosed reporting person | Aug. 5, 2022 | — | Initial filing | — | SEC |
| Undisclosed reporting person | Sept. 8, 2021 | — | Initial filing | — | SEC |
| Undisclosed reporting person | Nov. 3, 2020 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.